Sharemaestro Newsreel

Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares

Laurence W. Lytton has reported a beneficial ownership of 5,592,972 shares of Codexis, Inc. (CDXS) common stock, which represents a 5.2% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing with the SEC, indicating an increase in his holdings above …

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with …

Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Ocugen Inc. stock falls Thursday, underperforms market

Ocugen Inc. (OCGN) stock experienced a 3.57% decline on Thursday, closing at $1.35. This fall occurred despite a positive trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The decrease in Ocugen's stock price broke …

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 3.28% to $10.08, marking its third consecutive day of gains. This performance occurred on a strong trading day where the NASDAQ Composite Index increased by 0.81% and the Dow Jones Industrial Average rose by …

Curis prices $5.6 million public offering at $1.50 per share By Investing.com

Curis Inc. (NASDAQ:CRIS) has priced a public offering of 3,733,334 shares of common stock and warrants at $1.50 per share, aiming to raise approximately $5.6 million. The offering includes warrants exercisable at $1.75 per share, expiring in five years, and pre-funded warrants for some …

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

Mirum Pharmaceuticals (MIRM) saw its stock drop 6.4% despite raising its 2026 net product sales guidance, due to reporting significantly wider net losses in the second quarter of 2026. The company highlighted progress with breakthrough therapy designation for volixibat and potential launch timing for …

Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management

Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds …

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

Three analysts have issued bullish sentiments on healthcare companies Immunic (IMUX), Legend Biotech (LEGN), and Sagimet Biosciences, Inc. Class A (SGMT). William Blair reiterated a Buy rating on Immunic, H.C. Wainwright reiterated a Buy on Legend Biotech with a $65.00 price target, and Wedbush …

Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4%

Short interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) significantly increased by 223.4% to 135,370 shares as of July 31st. This represents approximately 0.6% of the company's shares outstanding and a days-to-cover ratio of 0.9 days. Despite mixed analyst sentiment with a consensus "Hold" …

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics reported strong second-quarter 2026 financial results with $101.9 million in consolidated revenue and $26.0 million in net income, driven by robust sales of DefenCath and contributions from the acquired Melinta portfolio. The company maintained its full-year 2026 revenue guidance and raised its …

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates

ProQR Therapeutics NV (NASDAQ: PRQR) reported second-quarter earnings per share that beat analyst estimates by €0.03, coming in at €-0.080 against an estimate of €-0.114. The company's revenue also surpassed expectations, reaching €8.76 million compared to the consensus estimate of €3.97 million. Despite these …

Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios

Janus Henderson Group Ltd. has disclosed an 8.4% passive ownership stake in Protara Therapeutics, Inc. (TARA) through its asset managers, holding 4,696,709 shares of common stock. These shares are managed on behalf of client accounts, referred to as Managed Portfolios, with Janus Henderson exercising …

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share …

Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

SueWallSt is investigating potential securities claims against Tenax Therapeutics (TENX) after its shares dropped 84-85% following the failure of its Phase 3 LEVEL trial of TNX-103 to meet primary and key secondary endpoints. Investors who suffered losses due to this decline are encouraged to …

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock, representing 14.0% of the class. These shares are held in client accounts, known as Managed Portfolios, where Janus Henderson's asset managers …

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. …

Celcuity LLC (CELC) enters earnings with mixed weekly signals

A near-term rebound contrasts with deeper medium-term losses before the oncology biotech reports.

Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management

Janus Henderson Group Ltd. has reported beneficial ownership of 172,229 shares of Janux Therapeutics, Inc. common stock, which represents a 0.3% stake in the company. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, and the group exercises …

Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A

An amended Schedule 13G filing for Eupraxia Pharmaceuticals (EPRX) reveals that Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank each report beneficial ownership of common shares ranging from approximately 4.1% to 4.5% of the …

Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates

Gossamer Bio Inc (GOSS) recently reported its Q2 2026 financial results, showing a loss but exceeding revenue estimates. The company, a clinical-stage biopharmaceutical firm, is focusing on developing seralutinib for pulmonary arterial hypertension. Several legal firms are investigating the company, and its stock has …

Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake

Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which …

Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus

Janus Henderson Group Ltd. has disclosed a 6.5% beneficial ownership stake in Tarsus Pharmaceuticals, Inc., totaling 2,808,796 shares of common stock. This ownership is held through its affiliated asset managers via Managed Portfolios, where they exercise investment and voting discretion. The filing indicates shared …

GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 118,715 shares of GeoVax Labs (GOVX) common stock through warrants. This represents a 1.59% stake based on 7,369,243 shares outstanding as of July …

Janus Henderson Group (ACHV) reports 5,502,064 Achieve Life shares under management

Janus Henderson Group Ltd., through its affiliated asset managers, has disclosed beneficial ownership of 5,502,064 shares of Achieve Life Sciences, Inc. (ACHV) common stock, representing 5.4% of the outstanding shares. These shares include those obtainable via warrants and are held in various Managed Portfolios, …

ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968

This page provides a detailed company profile for ADC Therapeutics SA, a Switzerland-based clinical-stage oncology drug discovery and development company. It outlines the company's business description, sales by activity and geographical breakdown, executive committee, board of directors, and major shareholders. Financial data, analyst consensus, …

Lenz drops as BofA downgrades on a slower VIZZ launch

[Republican Politics and Wall Street] Douglas Rissing Shares of Lenz Therapeutics (LENZ [https://seekingalpha.com/symbol/LENZ]) slipped for the third consecutive session on Thursday after Bank of America downgraded the eye drug developer to Neutral from Buy, citing a slower-than-expected rollout of its presbyopia therapy VIZZ. In …

Why is MeiraGTx stock surging today?

MeiraGTx Holdings PLC stock surged 6.3% following a dramatic beat on Q2 2026 earnings, reporting $1.71 EPS against an expected loss and revenue of $321.4 million. The company's financial turnaround was supported by strategic deals, FDA Breakthrough Therapy Designation, and a significantly strengthened balance …

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

SueWallSt is reminding shareholders of Replimune Group, Inc. (REPL) about a lead plaintiff deadline of October 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding the FDA's review of its RP1 resubmission, leading to an 84% …

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

Lenz Therapeutics' stock fell for the third straight day after Bank of America downgraded the company from Buy to Neutral. The downgrade was attributed to a slower-than-expected launch of its presbyopia therapy, VIZZ. Analyst Jason Gerberry also lowered his price target for LENZ.